However, it can be surmised that this biomarker will not be useful for patients receiving anti-GM-CSF antibodies therapeutically or patients with non-autoimmune pulmonary alveolar proteinosis whose condition is not characterized by GM-CSF autoantibodies2. This evidence concerns the gene CSF2 and autoimmune pulmonary alveolar proteinosis.